<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In response to concerns regarding the safety of ephedra-containing dietary supplements, manufacturers have marketed "ephedra-free" products </plain></SENT>
<SENT sid="1" pm="."><plain>Many of these contain <z:chebi fb="0" ids="29081">synephrine</z:chebi>, a <z:chebi fb="0" ids="35524">sympathomimetic</z:chebi> <z:chebi fb="39" ids="32952">amine</z:chebi> from the plant Citrus aurantium </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="29081">Synephrine</z:chebi> is structurally similar to ephedrine and has vasoconstrictor properties </plain></SENT>
<SENT sid="3" pm="."><plain>We describe a 38-year-old patient with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> associated with an ephedra-free <z:chebi fb="15" ids="50733">dietary supplement</z:chebi> containing <z:chebi fb="0" ids="29081">synephrine</z:chebi> and <z:chebi fb="111" ids="27732">caffeine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>The patient presented with <z:hpo ids='HP_0002354'>memory loss</z:hpo> and <z:hpo ids='HP_0002317'>unsteady gait</z:hpo> after taking 1 or 2 capsules per day of a <z:chebi fb="15" ids="50733">dietary supplement</z:chebi> (Stacker 2 Ephedra-Free) for 1 week </plain></SENT>
<SENT sid="5" pm="."><plain>He had no notable medical history or major atherosclerotic risk factors and took no other medications </plain></SENT>
<SENT sid="6" pm="."><plain>Physical examination showed a mildly <z:hpo ids='HP_0002066'>ataxic gait</z:hpo> and substantial Impairment of both concentration and memory </plain></SENT>
<SENT sid="7" pm="."><plain>Computed tomography and magnetic resonance Imaging of the brain showed <z:hpo ids='HP_0011011'>subacute</z:hpo> infarctions in the left thalamus and left cerebellum in the distribution of the vertebrobasilar circulation </plain></SENT>
<SENT sid="8" pm="."><plain>Other causes of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> were evaluated, and findings were unremarkable; a vasospastic origin was considered most likely </plain></SENT>
<SENT sid="9" pm="."><plain>The patient was discharged with nearly complete resolution of symptoms </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="29081">Synephrine</z:chebi>, a <z:chebi fb="0" ids="35524">sympathomimetic</z:chebi> <z:chebi fb="39" ids="32952">amine</z:chebi> related to ephedrine, may be associated with <z:hpo ids='HP_0002140'>Ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Consumers and clinicians need to be Informed about the potential risks of ephedra-free products </plain></SENT>
</text></document>